GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

The Asthma and Allergy Foundation of America has released its Asthma Capitals report, which ranks the 100 most populated U.S. states based on how challenging they are for people with the disease.

The new, free vaccine, Beyfortus, will be available to children up to 24 months old through their health care provider or at ...

Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...

The convergence of genetic engineering and artificial intelligence brings both the potential to revolutionize medicine and ...

Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...

British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...

GSK (GSK) reached the main goal in a Phase 3 trial for its RSV shot, Arexvy co--administered with Shingles vaccine Shingrix.

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...